Skip to main content

Table 1 Comparison of the baseline characteristic features between the two study groups

From: The effectiveness of pregabalin with or without agomelatine in the treatment of chronic low back pain: a double-blind, placebo-controlled, randomized clinical trial

Variable

Pregabalin ± Placebo (n = 23)

Pregabalin ± Agomelatine (n = 23)

P-value

Sex

• Male

• Female

3 (13)

20 (87)

13 (56.5)

10 (43.5)

0.001

Age

• < 30 years

• 30–40 years

• 40–50 years

• 50–60 years

3 (13)

4 (17.4)

5 (21.70

11 (47.8)

5 (21.7)

4 (17.4)

2 (8.7)

12 (52.2)

0.89

Disease duration

• < 1 month

• 1–12 months

• > 12 months

1 (4.3)

8 (34.8)

14 (60.9)

2 (8.7)

6 (26.1)

15 (65.2)

0.91

Education

• Undergraduate

• Bachelor

• Master

• Doctorate

15 (65.2)

6 (26.1)

1 (4.3)

1 (4.3)

15 (65.2)

8 (34.8)

0

0

0.9

Medicine taking

• Regular

• Irregular

22 (95.7)

1 (4.3)

23 (100)

0

0.96

Employment status

• Employed

• Unemployed

4 (17.4)

19 (82.6)

11 (47.8)

12 (52.2)

0.013

Marriage status

• Single

• Married

4 (17.4)

19 (82.6)

5 (21.7)

18 (78.3)

0.88

Body mass index

• > 24.9 Kg/m2

• 18.5–24.9 Kg/m2

• < 18.5Kg/m2

13 (56.5)

9 (39.1)

1 (4.3)

14 (60.9)

8 (34.8)

1 (4.3)

0.93

Smoking status

• Smoker

• Non-smoker

3 (13)

20 (87)

4 (17.4)

19 (82.6)

0.95

Physical activity

• Yes

• No

21 (91.3)

4 (8.7)

21 (91.3)

2 (8.7)

-

Family history of CLBP*

• Yes

• No

13 (56.5)

10 (43.5)

15 (65.2)

8 (34.8)

0.79

  1. *CLBP: Chronic low back pain
  2. Data are presented as mean ± SD or number (%). A P < 0.05 is considered significant